RuncheyResearch
Back to Forecasting

INSM Forecast Markets

Insmed Incorporated

7
Active Markets
53%
Avg Probability
Price Above Value
Apr 8, 2026

Our prediction ensemble identifies elevated risk at current levels.

7 markets analyzedConfidence: MEDIUM
Read Full Thesis

All Markets

7 markets

Will the ENCORE Phase III trial for ARIKAYCE meet its primary endpoint?

Active
50%
Likely No
97% agreement
Jun 30, 2026
IG: 1.00

Will BRINSUPRI net revenue exceed $200M in Q1 2026?

Active
57%
Likely Yes
97% agreement
May 15, 2026
IG: 0.80

Will BRINSUPRI generate $1B+ in net revenue for FY2026?

Active
43%
Likely No
97% agreement
Feb 28, 2027
IG: 0.80

Will BRINSUPRI repeat prescriber rate exceed 60% by mid-2026?

Active
50%
Likely No
97% agreement
Aug 15, 2026
IG: 0.64

Will BRINSUPRI's gross-to-net adjustment remain below 35% through FY2026?

Active
67%
Likely Yes
97% agreement
Feb 28, 2027
IG: 0.48

Will Insmed's quarterly operating cash burn stay below $300M in Q1 and Q2 2026?

Active
52%
Likely Yes
97% agreement
Aug 15, 2026
IG: 0.48

Will Insmed begin PALM-PAH Phase III enrollment by end of H1 2026?

Active
55%
Likely Yes
97% agreement
Jul 15, 2026
IG: 0.48

Resolution Timeline

May 15, 2026
Will BRINSUPRI net revenue exceed $200M in Q1 2026?
Prediction: 57%
Jun 30, 2026
Will the ENCORE Phase III trial for ARIKAYCE meet its primary endpoint?
Prediction: 50%
Jul 15, 2026
Will Insmed begin PALM-PAH Phase III enrollment by end of H1 2026?
Prediction: 55%
Aug 15, 2026
Will BRINSUPRI repeat prescriber rate exceed 60% by mid-2026?
Prediction: 50%
Aug 15, 2026
Will Insmed's quarterly operating cash burn stay below $300M in Q1 and Q2 2026?
Prediction: 52%
Feb 28, 2027
Will BRINSUPRI generate $1B+ in net revenue for FY2026?
Prediction: 43%
Feb 28, 2027
Will BRINSUPRI's gross-to-net adjustment remain below 35% through FY2026?
Prediction: 67%